Impaired hepatic apolipoprotein B and E translation in streptozotocin diabetic rats.
Studies of streptozotocin-induced diabetes in rats have demonstrated that hepatic apo B and apo E production are reduced. To determine if reductions are related to decreases in hepatic mRNAs, we performed blotting analysis of total liver RNA with rat apo B, apo E, and albumin cDNA probes. The expected reduction in albumin mRNA levels to 48% of control livers occurred in diabetic rat liver, while apo B and apo E mRNA levels were unchanged. The proportion of translational stop codon (BSTOP) mRNA averaged 43% of total in diabetic rats similar to control levels. Long-term labeling experiments using [35S]methionine in primary cultures of rat hepatocytes and specific immunoprecipitations demonstrated production of apo B and apo E, and albumin by hepatocytes from diabetic rats was reduced to 37%, 53%, and 23% of controls. Pulse-chase studies, together with mRNA analyses, suggest that reduced hepatic secretion of apo B and apo E in diabetics is primarily a result of impaired translation and not intracellular degradation. Ribosome transit studies directly confirmed the prolonged elongation rates for apo B and apo E mRNAs in hepatocytes derived from diabetic rats. This effect was more pronounced on apo BH (higher molecular weight) than on apo BL (lower molecular weight). Treatment of diabetic rats with insulin for 7 d led to normalization of hepatic albumin mRNA levels with no substantial change in apo E mRNA levels. In contrast, insulin treatment resulted in significant increases in hepatic apo B mRNA over control levels. Results suggest hepatic albumin and apo B mRNA levels are responsive to insulin in the diabetic state.
Sparks
J D
JD
Department of Pathology, University of Rochester, School of Medicine and Dentistry, New York 14642.
Zolfaghari
R
R
Sparks
C E
CE
Smith
H C
HC
Fisher
E A
EA
D000818:Animals; D001055:Apolipoproteins B / Q000235:genetics* / Q000378:metabolism; D001057:Apolipoproteins E / Q000235:genetics* / Q000378:metabolism; D001483:Base Sequence; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects; D007328:Insulin / Q000494:pharmacology; D008099:Liver / Q000503:physiopathology*; D008297:Male; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides / Q000737:chemistry; D010441:Peptide Chain Elongation, Translational / Q000187:drug effects*; D012323:RNA Processing, Post-Transcriptional; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D011919:Rats, Inbred Strains; D012270:Ribosomes / Q000378:metabolism; D012709:Serum Albumin / Q000235:genetics; D013311:Streptozocin
D001055:Apolipoproteins B; D001057:Apolipoproteins E; D007328:Insulin; D009838:Oligodeoxyribonucleotides; D012333:RNA, Messenger; D012709:Serum Albumin; D013311:Streptozocin